Optimizing Gastroenterology Myndshft Workflows with Klivira Automation

For gastroenterology practices, navigating the complex prior authorization landscape demands advanced automation. Klivira provides a platform that streamlines these critical 'Myndshft' category workflows, from high-volume biologics to advanced procedures, ensuring efficiency and compliance.

The operational burden of prior authorizations in gastroenterology is significant, driven by chronic conditions requiring high-cost biologics, frequent diagnostic and therapeutic procedures, and advanced imaging. Revenue cycle directors and prior authorization coordinators face persistent challenges in managing payer-specific rules, clinical documentation requirements, and frequent re-authorizations, impacting both patient access and practice profitability.

High-Volume Prior Authorization Triggers in Gastroenterology

Gastroenterology practices encounter a high volume of prior authorizations across several key categories. This includes biologics such as Humira, Stelara, Skyrizi, and Entyvio for IBD, as well as specialty IBD drugs. Procedures like colonoscopy, EGD, and advanced imaging such as MRCP and CT enterography also frequently trigger PA requirements, demanding precise documentation and timely submission.

Adhering to Clinical Guidelines and Documentation Standards

Payer policies for GI prior authorizations are heavily influenced by clinical guidelines from bodies such as ACG, AGA, and AASLD. For IBD biologics, documentation must confirm diagnosis, disease severity (e.g., Mayo score for UC, CDAI for Crohn's), and compliance with step therapy protocols, including prior conventional therapy trials. Hepatitis C direct-acting antivirals (DAAs) like Epclusa and Mavyret require genotype, fibrosis stage, and prior-treatment history.

Common Prior Authorization Denial Reasons in GI

Step therapy non-compliance for IBD biologics, often requiring trial of conventional agents or TNF inhibitors before non-TNF agents.
Mandated biosimilar substitution for brand-name TNF inhibitors, leading to denials if not followed.
Insufficient documentation of disease severity (e.g., missing Mayo score, CDAI) or screening (TB, hepatitis) pre-biologic initiation.
Gaps in fibrosis stage documentation or drug-drug interaction concerns for Hepatitis C DAAs.
Inappropriate-use criteria for advanced imaging or capsule endoscopy, lacking sufficient prior workup or clinical correlation.

Navigating Complex Gastroenterology Workflow Constraints

GI prior authorization workflows are uniquely challenging due to chronic treatment regimens for conditions like IBD, necessitating periodic re-authorizations every 6-12 months with continuous disease response documentation. The variability in biosimilar substitution policies across payers, coupled with the critical distinction between treatment-naive vs. treatment-experienced pathways for biologics and Hep C DAAs, adds layers of complexity. Furthermore, the split between medical and pharmacy benefits for biologics can complicate authorization routing and management.

Klivira's Intelligent Automation for Gastroenterology Workflows

Klivira's platform delivers robust automation to address the specific challenges of gastroenterology prior authorizations. Our system incorporates ACG/AGA-guideline-aware step therapy logic for IBD biologic sequencing and automates treatment-status classification from EMR medication history. We streamline Hep C DAA workflows by integrating genotype, fibrosis stage, and drug-interaction documentation. Additionally, Klivira manages periodic re-authorization cycles for chronic IBD biologics and facilitates accurate medical-vs-pharmacy benefit routing for biologic agent administration mode changes, reducing manual effort and denial rates.

Frequently asked questions

How does Klivira handle the distinction between medical and pharmacy benefit for GI biologics?

Klivira's platform intelligently routes prior authorization requests based on the specific administration mode of biologic agents. This ensures that whether a drug is provider-administered (medical benefit) or self-administered (pharmacy benefit), the correct payer channel and documentation requirements are met, adapting as patient treatment plans evolve.

Can Klivira help with step therapy compliance for IBD biologics?

Yes, Klivira incorporates guideline-aware step therapy logic aligned with ACG/AGA recommendations. The system helps identify and enforce payer-specific requirements for conventional therapy trials or preferred biologic sequencing, proactively flagging potential compliance issues to reduce denials.

How does Klivira support documentation for Hepatitis C DAA prior authorizations?

Our platform streamlines the collection and submission of critical documentation for Hep C DAAs, including genotype, fibrosis stage (e.g., FibroSure, transient elastography), and prior-treatment history. It also assists in managing drug-drug interaction reviews, a common requirement for these agents.

Does Klivira manage re-authorizations for chronic GI conditions?

Absolutely. For chronic conditions like IBD requiring ongoing biologic therapy, Klivira automates the periodic re-authorization workflow. The system tracks authorization expiry dates and prompts for necessary documentation of disease response, ensuring continuous coverage and minimizing treatment interruptions.

How does Klivira integrate with existing EMRs in gastroenterology practices?

Klivira offers seamless EMR integration, leveraging standards like SMART on FHIR where available, to pull patient demographics, medication history, diagnostic results, and clinical notes directly into the prior authorization workflow. This reduces manual data entry, enhances data accuracy, and accelerates the submission process.